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patient-specific organ masses including the respective errors 
and explain the difference between morphological and 
functional volume of organs), Scientific Problem Solving 
Service (K36: Explain the physics principles underpinning MR 
angiography (MRA) and flow, perfusion and diffusion imaging, 
functional MR imaging (fMRI) and BOLD contrast, MR 
spectroscopy (MRS), parallel imaging, DCE-MRI) and Clinical 
Involvement in D&IR (K88: Explain the use of the various 
modalities for anatomical and functional imaging and K90: 
Interpret anatomical and functional 2D/3D images from the 
various modalities and recognize specific anatomical, 
functional and pathological features). The curricula defines 
the SKC not specificying how MPE is involved in RT because 
the functional imaging (in general) and in radiotherapy (in 
particular), needs a strong interdisciplinary team: MPE expert 
in radiation oncology and MPE expert in functional imaging 
should approach the problem together with clinical support. 
The University and Accreditation training in Europe is not the 
same and each country differs: in many of them, MPE 
accreditation in Radiotherapy does not require the 
accreditation in Diagnostic Imaging. In the next future, 
requirements of physics application in radiotherapy willneed 
to include the expertise in diagnostic imaging with particular 
attention to functional imaging, but the interdisciplinary 
approach is more effective in the clinical practice. EFOMP 
and ESTRO working Group is working to define the potential 
topics for MPE education and training e-learning platform; 
the knowledge and the expertise in this field will be more 
and more important. 
 




The need of automation in QA, state of art and future 
perspectives 
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From the earliest times mankind has struggled to improve his 
productive means; skills, tools and machines. Aristotle 
dreamed of the day when “every tool, when summoned, or 
even of its own accord, could do the work that befits it”. 
However, we have to wait till 1956 to see the name 
“automation” appearing in dictionaries. Automation was 
defined as: “the use of various control systems for operating 
equipment such as machinery, processes in factories, aircraft 
and other applications with minimal or reduced human 
intervention”. In the fifties it was heralded as the threshold 
to a new utopia, in with robots and “giant brains” would do 
all work while human drones reclined in a pneumatic bliss. 
The pessimists pictured automation as an agent of doom 
leaving mass unemployment and degradation of the human 
spirit in its wake. Sixty years from those first papers and 
books in automation we can see that neither the optimistic 
perspectives nor the most catastrophic views have come 
true; we still have to wake up to go to work each morning 
and job have changed but not disappeared. The use of 
automation in different fields is not homogeneous. For 
instance, planes, trains and ships are already heavily 
automated while in our field, radiation oncology and 
medicine in general, automation has not been fully 
exploited. Repetitive tasks can be easily automated and this 
will on one side avoid tedious thinking that must be done 
without error and on the other side will free time to more 
creative thinking which will satisfy and give us more joy. 
Treatment planning, evaluation of treatment planning and QA 
at treatment unit are areas that are being explored by 
different research groups. We can automate tasks but 
automations means much more than this. Automation is a 
means of analysing, organising and controlling our processes. 
But how far can we go? Can we design a system able to take 
complex decisions and not only binary ones such as pass/fail 
for a quality control test? Yes we can, if we exploit machine 
learning algorithms. Machine learning will be able to predict 
the best possible solution for a particular problem and will 
form the core of both quality control methods (comparing the 
predictions with the actual results). One of the side products 
of automation is standardisation of practice. Let’s take 
treatment planning as an example. Treatment planning is a 
time consuming task and the resulting plans depend largely 
on the ability of the planer. Automation in treatment 
planning has shown to reduce the time needed to achieve 
plans with less variability and quality. The fact that most 
vendors offer the possibility of writing scripts to automate 
checks and to query treatment machine log-files and 
treatment planning systems data is welcomed and will 
facilitate the clinical implementation of automation. For 
management, automation poses the problem of adapting to 
new concepts and new methods of working and the processes 
have to be adjusted. Risk analysis has to be re-evaluated and 
probably different risk mitigation strategies will have to be 
implemented. For the worker, automation involves changes 
in the way of working. In particular, clinical medical 
physicists will have to design performance tests to evaluate 
these automated systems. To face the challenges that 
automation brings to our field, medical physics curricula 
should include IT and also programming. With automation 
comes a choice between additional leisure and additional 
products. I would strongly advocate for more time for 
scientific creative thinking which is needed to contribute to 
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The need of QA for individual treatment plans 
The achievable degree of organ sparing with radiation 
treatment planning is highly dependent on the patient 
anatomy. Radiation treatment planning with a commercial 
TPS is an iterative trial and error process. Even for 
experienced dosimetrists or physicians it is very difficult to 
judge whether the dose to OARs cannot be lowered further. 
As a result, the quality of a treatment plan is highly 
dependent on the available planning time, the experience 
and talent of the treatment planner and how critically the 
treatment plan is being reviewed. In a recent study by our 
group it was shown that after trying to further improve 
already approved IMRT treatment plans for prostate cancer 
patients, the rectum dose could be further reduced by on 
average 6 Gy (range 1-13 Gy), without negative consequences 
for PTV or other OARs [1]. In conclusion, there is a clear need 
for treatment planning quality assurance (QA) protocols to 
guarantee that for each patient the generated plan is indeed 
optimal for the patient-specific anatomy.  
 
Different strategies for treatment planning QA 
In recent years different groups have proposed different 
strategies for treatment planning QA. The general idea is to 
predict the lowest achievable dose for OARs and compare the 
achieved dose of the treatment plan with the predictions. As 
long as differences between the predictions and the achieved 
doses to the OARs exceed some predefined action levels, 
treatment planning should continue, to try to further lower 
the doses. Most methods rely on a database with plans of 
prior patients treated for the same tumor site. Because the 
achievable degree of OAR sparing is highly dependent on 
patient anatomy only treatment plans of prior patients with 
anatomies similar as the new patient are selected. Next 
these prior plans are used to predict achievable DVH metrics 
for the new patient. The main distinctions between the 
different methods are (i) the manner in which similarity in 
anatomy is assessed and (ii) how the dose distributions of the 
similar prior patients are used to predict DVH parameters for 
new patients. 
Similarity in anatomy can be assessed using distinctive 
anatomical features. These can vary from very simple such as 
the percentage overlap of the PTV with an OAR[2]; to an 
intermediate level of complexity such as the Overlap Volume 
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Histogram that quantifies in 1D the orientation and position 
of an OAR to the PTV[3]; to more complex such a non-rigid 
registration based [4]. Also the strategies to predict the dose 
based on the selected patients vary in complexity: from the 
lowest achievable dose among all more “difficult” patients 
[5], to principal component analyses that combine achieved 
doses of multiple patients and organs to make the predictions 
[6]. Different models have been successfully applied for 
prostate, head-and-neck, pancreatic and lung cancer patients 
[2, 4, 7, 8]. 
 
Evaluation of the performance of different treatment 
planning QA models 
An important challenge for the development of treatment 
planning QA models is that the plans to train and validate the 
models are often generated with the same trial and error 
treatment planning process, as where the treatment planning 
QA models are intended for in the first place. Suboptimal 
plans used for training and validation could lead to 
suboptimal models, a bias in the evaluation of the prediction 
accuracy, suboptimal action levels and difficulties to 
compare different models that were trained on different 
patients cohorts. Therefore, recently our group has 
generated a dataset of 115 Pareto optimal IMRT treatment 
plans for prostate cancer patients that were planned fully 
automatically with consistent prioritization between PTV 
coverage, sparing of organs at risk, and conformality (see 
abstract Wang, Breedveld, Heijmen, Petit). This dataset has 
been made publicly available and can be used for objective 
validation of existing and development of new treatment 
planning QA models. 
 
Conclusion 
There is a need for treatment planning QA models to assess 
whether a generated treatment plan is indeed optimal for 
the patient specific anatomy. Different models have been 
proposed for this purpose that vary in complexity. There are 
currently some challenges for clinical implementation, but 
these are likely to be solved in the near future.  
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Purpose 
The purpose of thispresentation is to show the capabilities of 
treatment unit log files for QA, aswell as their limitations. To 
this aim, the implementation of a QA Programbased on 
Varian dynalogs is presented together with the results 
obtained. Thepossibility of replacing phantom-based 
pretreatment QA by log file analysiswill also be discussed 
during the presentation. 
QA Program 
The QA Program wasdeveloped with in-house software, in 
particular with Java (dynalog analysis), MATLAB® (fluence 
calculation andcomparisons) and MySQL (data storage and 
reports). Three Varian linacs wereevaluated and >60,000 
dynalogs were analyzed, corresponding to both slidingwindow 
and VMAT techniques. 
As part of this QA Program,all IMRT beam deliveries were 
verified by the following tests: 
· Analysis of the RMS (Root Mean Square) values of leaf 
positionalerrors. RMS values from different deliveries of the 
same beams were verystable, with differences between 
different fractions <0.05mm in over 99.9%of the cases. This 
shows that the MLC positioning is extremely reproducible. 
· Analysis of the maximum leaf positioning deviations. 
Maximumdeviations were typically within 1-1.5mm and 
depended mainly on the maximumleaf speed. 
· Incidence of beam hold-offs and beam interruptions. The 
meanincidence was 1 hold-off for every 3 dynamic beams 
deliveries and <1% beamswith interruptions (related to any 
kind of interlock). 
· Comparison of the planned fluence and the actual 
fluencecomputed from dynalogs. Excellent agreement was 
obtained, with passingrate>98% for gamma 1%/1mm in 
practically all cases (>99.9% of the beams). 
Limitations and validation of dynalogs 
In general, the accuracy oflog files is unclear, especially if 
they come from non-independent systems.Information in 
Varian dynalogs comes from the MLC controller, that is, from 
thesame motor encoders that drive the MLC. For this reason, 
dynalog files will NOTdetect errors due to MLC calibration 
parameters (dosimetric leaf gap, offset,skew), motor count 
losses or backlash. Indeed, Varian dynalogs must becarefully 
validated by experimentally checking the accuracy of MLC 
positioning,preferably at different gantry angles and at the 
end of the treatment day (dueto the cumulative effect of 
motor count losses since MLC initialization). 
Another limitation ofdynalogs is that several aspects of 
treatment delivery are not recorded in logfiles (beam 
symmetry, homogeneity, energy…). However, these other 
aspects arenot specific to IMRT treatments and should be 
verified as part of the routinestandard QA Program. 
Conclusions 
Logfile analysis allows exhaustive monitoring of MLC 
performance and other machineparameters. 
Implementing a QA Programbased on dynalogs makes it 
possible to control data transfer integrity and ALLtreatment 
deliveries (the entire course of treatment). 
Theefficiency of QA can be increased with a fully automated 
and integrated QAprogram based on log file analysis. 
Commercial software is available which alsoincorporates 
independent dose calculations. 
Log file analysis providesa useful complement to a general 
‘conventional’ QA program. However, validationof log files 
against measurements isneeded. In Varian environments, 
daily experimental verification of theMLC positioning, 
preferably at different gantry angles and at the end of 
thetreatment day, is strongly recommended. 
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Over the last years, the efficacy of radiation oncology 
treatmentsimproved dramatically. However, due to the 
increase in technical complexity anddose escalation, the risk 
of secondary effects also rises. In vivo dosimetry(IVD) is now 
widely recommended to avoid major treatment errors and is 
evenmandatory in several countries. 
In this perspective, transit dosimetry using amorphous 
siliconElectronic Portal Imaging Devices (EPID) appears to be 
an interesting solutionfor several practical reasons (easy to 
use, no additional time, no perturbationin the beam, 2D 
detectors, complex techniques possible, numerical data, 
etc…). Forall these reasons, daily controls for every patient 
becomes realistic. However,with constrained resources 
(staffing, time, etc…), this will become feasible in the clinic 
by means of automated systems.Medical physics teams will 
then be able to set and managea permanent survey system: 
· To verify the actual radiation dosedelivered to the patient 
during the procedure 
· Detect errors before it is too late 
